Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
92.50    0.00 (0.00%)
Bid:
90.00
Ask:
95.00
Spread: 5.00 (5.556%)
Market Cap: £6.08m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Trading Update and Contract Rollout

14 Dec 2016 07:00

RNS Number : 7707R
Crimson Tide PLC
14 December 2016
 

CRIMSON TIDE PLC

 ("Crimson Tide" or "the Company")

 

TRADING UPDATE AND CONTRACT ROLLOUT

 

Crimson Tide, the provider of mpro5 ‐ Smart Mobility as a Service, is pleased to provide a trading update for the year ending 31 December 2016. Revenue is expected to total not less than £1.75 million, an improvement of approximately 25% on the prior year, whilst Profit after Tax is expected to have more than doubled. Cash generation has continued to be strong and the year-end position will be significantly higher than for the year ended 2015. This performance is in line with market expectations, and includes the cost of some early investments in growth for 2017 and beyond.

 

The Company has won a number of important contracts throughout the year, including:

· its largest contract to date with a major UK supermarket, representing the Company's second supermarket client;

· a long term agreement with the National Centre for Hereditary Coagulation Disorders (NCHCD) in Ireland; and

· an increased value contract extension with Interserve, the international support services and construction group.

 

Since winning the contract with a second supermarket, the Company can now report that rollout of the solution has happened faster than forecast and revenues are being recognised for the full number of stores. Financing related devices was again arranged with Lombard Technical Services.

 

These contracts provide strong revenue visibility for next year and beyond, giving the Board the confidence to invest further in the business to take advantage of the considerable market opportunity. The sales and marketing team has already been increased and is starting to result in more new opportunities for the Company and, following the success of our partnership in Ireland, we have also begun to invest in further international expansion and would expect to announce developments in this area in due course. Whilst this will increase the cost base, the Board is confident that these measures will generate greater returns for shareholders.

 

The Company is also pleased to announce that Luke Jeffrey, Technical Director, has been promoted to the position of Deputy Chief Executive Officer.

 

Barrie Whipp, Executive Chairman, commented "We have continued to win profitable, cash generative business with high levels of visible, recurring revenue from major organisations. These contracts provide a very stable platform from which to continue to grow the business but also excellent reference sites for attracting new customers, which is always a key challenge for smaller companies. Our team has doubled in number in 18 months and we expect our results to show a doubling of profits for the second year in a row. This gives us the resources and confidence for sound strategic investments which will enable us to drive the business forward aggressively in 2017 and beyond. The Board is very confident for the future"

 

For further information:

 

Crimson Tide plc

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Alma PR

Josh Royston 07780 901 979

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUOAWRNBAUAAA
Date   Source Headline
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company
23rd Apr 202110:37 amRNSPDMR Dealings
23rd Apr 202110:36 amRNSHolding(s) in Company
22nd Apr 202111:45 amRNSResult of General Meeting and Total Voting Rights
20th Apr 20217:00 amRNSContract Win
1st Apr 20213:52 pmRNSResult of Placing
1st Apr 202112:01 pmRNSPlacing to raise up to £6.0 million
1st Apr 202112:00 pmRNSPreliminary Results
18th Mar 20217:00 amRNSContract Win
1st Feb 20219:28 amRNSHolding(s) in Company
28th Jan 20217:00 amRNSAppointment of Director
26th Jan 20217:00 amRNSPilot with World Federation of Haemophilia
18th Jan 20219:36 amRNSHolding(s) in Company
12th Jan 20214:07 pmRNSHolding(s) in Company
7th Jan 20212:30 pmRNSHolding(s) in Company
23rd Dec 202012:15 pmRNSClarification re Grant of Options
22nd Dec 202010:45 amRNSGrant of Options under the Company's EMI Scheme
4th Dec 202011:35 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSContract Wins
12th Nov 20204:27 pmRNSDirector/PDMR Shareholding
6th Nov 20201:15 pmRNSPDMR dealing
26th Oct 202010:08 amRNSHolding(s) in Company
5th Oct 20209:16 amRNSHolding(s) in Company
18th Sep 20207:00 amRNSInterim Results
14th Sep 20202:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.